Results 101 to 110 of about 10,135 (204)

Class A drug abuse: an ophthalmologist's problem? [PDF]

, 2005
[First Paragraph] The 2002/3 British Crime Survey reported that 3% of all 16 to 59 year olds (equating to around one million people) had used a class A drug in the last year.
Firth, A.Y.
core   +1 more source

Thyroid associated orbitopathy with ocular myasthenia in primary hypothyroidism: Keep those eyes open

Indian Journal of Endocrinology and Metabolism, 2013
Thyroid associated orbitopathy, although seen most commonly with thyrotoxicosis, is also known to occur in primary hypothyroidism. Myasthenia gravis is an autoimmune condition with an established association with autoimmune thyroid disease. We report the
Chitra Selvan, Deep Dutta, Indira Maisnam, Anubhav Thukral, P P Chakraborthy, Ajitesh Roy, Rakesh Arora, Soumik Dutta, Arjun Baidya, Sujoy Ghosh, Satinath Mukhopadhyay, Subhankar Chowdhury   +11 more
doaj   +1 more source

Neurological complications of immune checkpoint inhibitors: what happens when you \u27take the brakes off\u27 the immune system. [PDF]

, 2018
Patients with advanced malignancies treated with immune checkpoint inhibitors are at increased risk for developing immune-related neurological complications.
Dalakas, Marinos
core   +1 more source

Ocular Myasthenia Gravis and Thymus Gland Hyperplasia–A Case Report

TNOA Journal of Ophthalmic Science and Research
Myasthenia gravis (MG) is caused by antibodies directed at acetylcholine receptors or functionally related proteins in the postsynaptic membrane at the neuromuscular junction.
Sujit Das
doaj   +1 more source

Single-fiber electromyography in the orbicularis oculi muscle in patients with ocular myasthenia gravis symptoms: does abnormal jitter predict response to treatment?

BMC Neurology, 2017
Background Seronegative ocular myasthenia gravis (OMG) is diagnosed by ocular symptoms with supporting SFEMG, typically of frontalis or extensor digitorum muscles.
Goran Rakocevic, Mark Moster, Mary Kay Floeter   +2 more
doaj   +1 more source

ROLE OF THYMECTOMY IN MYASTHENIA GRAVIS [PDF]

, 1992
Thirteen patients with myasthenia gravis underwent total thymectomy between January, 1988 and December, 1991. The duration of symptoms prior to surgery varied from 2 months to 20 years.
Ali, Sohaila Mohsin, Altafullah, Irfan, Sheikh, Hizbullah, Sonawalla, Aziz   +3 more
core   +1 more source

Unsatisfactory outcomes in myasthenia gravis: influence by care providers [PDF]

, 2018
Myasthenia gravis (MG) can be difficult to treat despite an available therapeutic armamentarium. Our aim was to analyze the factors leading to unsatisfactory outcome (UO).
Borruat, François-Xavier, Botez, Stephan, Dunand, Murielle, Kuntzer, Thierry, Roux-Lombard, Pascale, Spertini, François   +5 more
core  

Thirteen years follow-up after radical transsternal thymectomy for myasthenia gravis. Do short-term results predict long-term outcome? [PDF]

, 2017
Objective: Long-term evaluation of efficacy and quality of life after radical surgical approach for myasthenia gravis (MG). Comparison between short-term follow-up and long-term outcome.
Ackermann, R., Inderbitzi, R., RoslerRösler, K., Roth, T., Schmid, R.A., Stein, R.   +5 more
core  

Оцінка тривожності у хворих на міастенію [PDF]

, 2018
У статті представлено результати дослідження тривожності у хворих на міастенію залежно від імунологічного типу, тривалості та клінічної форми захворювання. Мета роботи — дослідити рівень тривожності у дорослих, хворих на міастенію. Матеріал і методи.
Кальбус, О.І.
core  

Study of differential cytokine IFN-γ,IL-10，TGF-β and IL-17 level in patients with myasthenia gravis with antibodies against AChR ,MuSK and LRP4 [PDF]

, 2016
目的:通过采用酶联免疫吸附(ELISA)法检测重症肌无力(myastheniagravis，MG)患者血清乙酰胆碱受体抗体(AChR-Ab)，肌肉特异性酪氨酸激酶抗体(MuSK-Ab)，低密度脂蛋白受体相关蛋白4抗体（LRP4-Ab）浓度，探讨AChR-Ab，MuSK-Ab，LRP4-Ab与重症肌无力临床分型、及与细胞因子干扰素-γ(IFN-γ)，白细胞介素-10（IL-10），生长转化因子-β（TGF-β），白细胞介素-17（IL-17）的关系。 方法： 1.本研究分为重症肌无力组和健康对照组 ...
李若冰
core